Alvanidis et al. stated that venetoclax, a selective BCL-2 inhibitor, appears to be a promising therapy for patients with relapsed/refractory AL amyloidosis, particularly in patients with the t(11;14) translocation and plasma cell leukemia. Here, BCL2 is linked to AL amyloidosis.